Novartis

Cancer drug to treat dwarfism? Abandoned Novartis asset snagged by BridgeBio’s QED Therapeutics
Cancer drug to treat dwarfism? Abandoned Novartis asset snagged by BridgeBio’s QED Therapeutics
Endpoints
Novartis
dwarfism
infigratinib
BridgeBio
Flag link:
FDA approves Novartis-acquired Lutathera for certain gut cancers
FDA approves Novartis-acquired Lutathera for certain gut cancers
Biopharma Dive
Novartis
FDA
Lutathera
Flag link:
Pharma gets a seat at the table at private dinner with Trump at Davos
Pharma gets a seat at the table at private dinner with Trump at Davos
Stat
Donald Trump
pharma industry
Vas Narasimhan
Novartis
Werner Baumann
Bayer
Flag link:
Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout
Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout
Endpoints
Novartis
Lutathera
FDA
neuroendocrine tumors
Flag link:
Novartis move signals further gene therapy resurgence
Novartis move signals further gene therapy resurgence
EP Vantage
Novartis
gene therapy
Spark Therapeutics
CAR-T
Luxturna
Flag link:
Here is the salary of new Novartis CEO Vas Narasimhan
Here is the salary of new Novartis CEO Vas Narasimhan
GoinPharma
executive pay
Novartis
Vas Narasimhan
Flag link:
Spark licenses blindness gene therapy rights outside U.S. to Novartis
Spark licenses blindness gene therapy rights outside U.S. to Novartis
Yahoo/Reuters
Spark Therapeutics
Novartis
Luxturna
gene therapy
Flag link:
Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto
Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto
NASDAQ.com
Novartis
earnings
Cosentyx
Entresto
Flag link:
Big day looming, Novartis’ new CEO Vas Narasimhan readies his jump into a marketing melee
Big day looming, Novartis’ new CEO Vas Narasimhan readies his jump into a marketing melee
Endpoints
Novartis
Pharma CEOs
Vas Narasimhan
Joe Jimenez
Flag link:
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.
Fierce Pharma
Novartis
Arzerra
Genmab
CLL
chronic lymphocytic leukemia
Flag link:
Novartis ties a new round of biosimilar development programs to a partnership deal with India’s Biocon
Novartis ties a new round of biosimilar development programs to a partnership deal with India’s Biocon
Endpoints
Novartis
Biocon
drug development
biosimilars
Flag link:
Novartis aims for US approval of Humira biosimilar
Novartis aims for US approval of Humira biosimilar
Biopharma Dive
Novartis
Humira
biosimilars
AbbVie
Sandoz
Flag link:
Novartis goes 2-0 against J&J in psoriasis
Novartis goes 2-0 against J&J in psoriasis
Biopharma Dive
Novartis
JNJ
psoriasis
Cosentyx
Stelara
Flag link:
Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
Yahoo/Zacks.com
Novartis
psoriasis
Cosentyx
biosimilars
ankylosing spondylitis
Flag link:
Novartis Pharma Ex-CEO takes three roles in two days
Novartis Pharma Ex-CEO takes three roles in two days
Pharmafile
Novartis
Pharma CEOs
David Epstein
Axcella Health
Rubius
Flag link:
Cancer Space Update: New Regulatory Status for 3 Major Drugs
Cancer Space Update: New Regulatory Status for 3 Major Drugs
Yahoo/Zacks.com
cancer
Merck
Japan
Keytruda
Seattle Genetics
Adcetris
Novartis
Kisqali
Flag link:
Pfizer, Novartis and more post price hikes on dozens of drugs, but AbbVie’s is worth the most
Pfizer, Novartis and more post price hikes on dozens of drugs, but AbbVie’s is worth the most
Fierce Pharma
drug pricing
Pfizer
Novartis
AbbVie
Flag link:
Novartis Gets Second Breakthrough Designation for Kisqali
Novartis Gets Second Breakthrough Designation for Kisqali
Yahoo/Zacks.com
Novartis
Kisqali
breast cancer
Flag link:
Top 10 stories that had pharma execs talking
Top 10 stories that had pharma execs talking
Biopharma Dive
M&A
Bristol-Myers Squibb
Opdivo
Express Scripts
Novartis
C-ART
Kymriah
Massachusetts
AbbVie
Kenneth Frazier
biosimilars
CVS Health Pfizer
Flag link:
Ruling Against Novartis Could Have Wider Implications for Generic Drug Labels
Ruling Against Novartis Could Have Wider Implications for Generic Drug Labels
RAPS.org
Novartis
generics
California
Flag link:

Pages